comparemela.com

Latest Breaking News On - Forbion european acquisition corporation - Page 1 : comparemela.com

enGene Announces Hiring of Dr Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead.

United statesChapel hillRichard bryceRaj pruthiDerivatized oligochitosanJason hansonExchange commissionGene holdings incUniversity of north carolinaDgene incGuidelines committeeUniversity of north carolina at chapel hillForbion european acquisition corporationClinical developmentMaster of health administrationDuke university school of medicine

/C O R R E C T I O N -- enGene Inc /

In the news release, engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development, issued 09-Apr-2024 by enGene Inc., the headline was incorrectly.

United statesChapel hillDerivatized oligochitosanRaj pruthiRichard bryceJason hansonExamination committeeDepartment of urologyUniversity of north carolina at chapel hillHofstra university northwellExchange commissionAdvisory council for urologyCompany annual report on formGene holdings incAmerican urological associationGuidelines committee

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

/PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead.

United statesJason hansonDerivatized oligochitosanLota zothDgene incForbion european acquisition corporationExchange commissionCompany board of directorsCompany annual report on formCompany audit committee chairGene holdings incGene holdingsChief executive officerBusiness highlightsOversubscribed private placementHercules capital debt facility

EnGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private.

United statesLota zothDerivatized oligochitosanJason hansonGene holdings incDgene incCompany audit committee chairForbion european acquisition corporationExchange commissionCompany annual report on formCompany board of directorsGene holdingsChief executive officerBusiness highlightsOversubscribed private placementHercules capital debt facility

EnGene Announces Leadership Succession Plan

BOSTON and MONTREAL, Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. , a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive.

United statesDerivatized oligochitosanRichard glickmanJason hansonForbion european acquisition corporationCompany annual report on formGene holdings incExchange commissionGene holdingsChief executive officerRgene boardBacillus calmette guDually derivatized oligochitosanPrivate securities litigation reform actAnnual report

vimarsana © 2020. All Rights Reserved.